23 results about "Bevacizumab" patented technology

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

A single-cell transcriptome-guided multimodal synergistic injectable magnetically responsive biomimetic hydrogel system, its preparation method, and its application are described. This hydrogel platform is a three-level composite system of "matrix-microsphere-nanoparticle": the primary structure is a photocrosslinked methacryloyl hyaluronic acid three-dimensional network matrix; the secondary structure is GelMA microspheres loaded with MTPT nanoparticles prepared by microfluidic control; and the tertiary structure consists of bevacizumab and magnetite nanoparticles dispersed in the HAMA matrix. The MTPT nanoparticles have a mesoporous silica core, which is sequentially coated with temozolomide, a polydopamine coating, and a T7 targeting peptide. Under the activation of an alternating magnetic field, Fe3O4 generates a magnetothermal effect, which not only achieves local hyperthermia but also accelerates the time-sequential release of bevacizumab and MTPT, synergistically exerting the effects of chemotherapy, anti-angiogenic therapy, and hyperthermia.

Disclosed are kits and methods for detecting whether a patient with metastatic colorectal cancer should receive AVASTIN® (bevacizumab) in addition to chemotherapy.

The application provides application of bevacizumab in preparation of a medicine for inhibiting hemorrhagic lesions of cerebral vascular malformations, and belongs to the technical field of medicine application. The application firstly discovers and proves by experiments that bevacizumab can be used for binding free VEGF molecules in serum of a patient with a cavernous cerebral vascular malformation, thereby inhibiting a VEGF path, and having obvious inhibiting effect on symptomatic hemorrhagic lesions of the cavernous cerebral vascular malformation, and developing a new use of bevacizumab, and providing a new selection of drug treatment for the patient with the cavernous cerebral vascular malformation.

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.

The invention focuses on developing final ophthalmic dosages based on Sildenafil associated with bevacizumab, known for its retino-protective properties, aimed to preserve and improve visual functions, particularly in patients with retinal degenerative disease specially for the dry form of macular degeneration

The application belongs to the field of protein purification, and relates to a method for preparing bevacizumab, comprising the steps of affinity chromatography, virus inactivation, deep filtration, composite anion exchange chromatography, cation exchange chromatography and the like.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The invention belongs to the technical field of medicines, and discloses a method for promoting drug resistance of triple negative breast cancer bevacizumab by driving IGF2BP3 lactic acid modification through PARK7, and milk acylation modification (IGF2BP3-K76lac) of lysine at the 76th site of IGF2BP3 protein is a key driving factor of drug resistance of bevacizumab. The overexpression of the IGF2BP3-K76lac can obviously enhance the drug resistance of the bevacizumab, and the overexpression of the IGF2BP3-K76lac is verified in both in-vitro experiments and in-vivo models. From the perspective of a molecular mechanism, the milk acylation modification at the IGF2BP3K76 site can enhance the binding capacity of the IGF2BP3K76 site and m6A modified FSP1 mRNA, so that the expression level of FSP1 is up-regulated, and finally the cells are endowed with ferroptosis resistance. By blocking the IGF2BP3-K76lac, ferroptosis induced by bevacizumab can be remarkably enhanced, the antioxidant defense mechanism of an organism is destroyed, and tumor growth is inhibited. In addition, PARK7 functions as a milk acyltransferase, and enhances the binding ability of IGF2BP3-K76lac to promote the function thereof. And finally, the blocking antibody targeting IGF2BP3-K76lac is proved to have a synergistic effect with the bevacizumab, so that the sensitivity of the bevacizumab is effectively recovered.

The application relates to the technical field of biological medicine, and particularly discloses a bifunctional fusion protein and application thereof in treating retinal degenerative diseases. The fusion protein is named Beva-1L, which is formed by fusing an amino acid sequence of human brain-derived neurotrophic factor (BDNF) with a light chain of an anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab. The fusion protein can simultaneously inhibit VEGF-mediated pathological angiogenesis and provide neurotrophic support, and is used for treating retinal degenerative diseases such as diseases simulated by an rd10 mouse model. Experiments show that the amplitude of a retinal electrogram (ERG) of the rd10 mouse can be significantly improved by injecting the Beva-1L, and the effect is equivalent to that of a positive drug. The application also relates to a coding gene, an expression vector, a host cell, a pharmaceutical composition of the fusion protein and application thereof. The fusion protein has a bifunctional synergistic effect, and provides a new treatment strategy for retinal degenerative diseases.

The invention discloses a bispecific antibody targeting heterogeneous macrophages, and relates to the field of biological medicines. According to the present invention, bevacizumab is adopted as a parent antibody skeleton, antibody arms targeting CD16 are arranged on the N end side, antibody arms targeting CD163 are located on the C end side, knob mutation (K322A and T366W) is introduced into the heavy chain CH3 structural domain targeting CD16, three complementary hole mutations (T366S, L368A and Y407V) are introduced into the heavy chain CH3 structural domain targeting CD163, and cysteine residues are inserted into the S354 site of the knob chain and the Y349 site of the hole chain; variable regions (V regions) targeting CD16 and CD163 are connected in series through a (G4S) 3 flexible linker and then fused with respective constant regions (C regions). The double-antibody architecture disclosed by the invention realizes collaborative optimization in structural stability, double-antigen binding specificity, macrophage targeting and functional activity, provides an efficient and safe novel candidate drug for targeted therapy of related diseases, and has important clinical transformation value and application prospect.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

The present application relates to methods of stimulating an immune response in a subject by administering to the subject (i) an antibody that binds human IL-27 or an antigen binding portion thereof (an anti-IL-27 antibody), (ii) toripalimab, and (iii) bevacizumab. Methods of treating a cancer by administering (i) an antibody that binds human IL-27 or an antigen binding portion thereof (an anti-IL-27 antibody), (ii) toripalimab, and (iii) bevacizumab are provided.

The efficacy and indication of bevacizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The invention relates to a vesicle loaded with Bevacizumab and a preparation method and application thereof.The vesicle is formed by mixing cell membrane nano vesicles and platelet membrane nano vesicles which encode TIGIT genes, the mass ratio of the cell membrane nano vesicles to the platelet membrane nano vesicles is (1-10): 1, the vesicles encapsulate Bevacizumab, and the vesicles can specifically target liver and TZ, inhibit neovascularization and improve the activity of TZ. And the anti-tumor function of the CD8 + T cells is recovered. Research results show that BevatTPNV can effectively inhibit liver metastasis after MWA. Compared with a control group, the intrahepatic metastasis load is reduced by about 10 times, and the survival rate of mice within 70 days reaches 50%. The work is expected to establish a new standard treatment mode, and the combined immunotherapy after hepatic metastatic tumor ablation can be thoroughly changed.

A use of Apicidin combined with Bevacizumab in preparing a drug for treating cervical cancer is provided. Studies have shown that Apicidin increases the sensitivity of cervical cancer cells to the targeted drug Bevacizumab. The combined use of Apicidin and Bevacizumab can more effectively inhibit the growth of cervical cancer cells and enhance the ability to induce apoptosis of cervical cancer cells, showing a good synergistic effect. Therefore, the use prospects of Apicidin combined with the targeted drug Bevacizumab are huge, which provides a more effective and feasible solution for the clinical treatment of cervical cancer, and proposes a new theoretical basis for the combined treatment of clinical cervical cancer recurrence and drug resistance.

Treatment combinations are provided for FOLR1-binding immunoconjugates (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin. Methods for administering said combinations to treat cancers, such as ovarian cancer, with increased clinical efficacy and / or reduced toxicity are also provided.

The application belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of TACE combined with sindibimab and bevacizumab in treating hepatocellular carcinoma and a construction method and application of a FAAP prognosis scoring model. The application develops and verifies a FAAP prognosis scoring system, a new type of composite model integrating four indexes of fibrin degradation product / cholinesterase ratio x 1000 (FCR), aspartate aminotransferase (AST), alpha-fetoprotein (AFP) and portal vein tumor thrombus (PVTT), for predicting the survival of uHCC patients receiving TACE-sindibimab-bevacizumab triple therapy. The tool has instant clinical value, can optimize patient selection, guide adaptive treatment upgrade, and provide a standardized efficacy evaluation basis for exploring the clinical trials of TACE-immunotherapy-anti-angiogenesis combined schemes.

The invention provides a large-scale multiplication culture method of CAR-T cells, and belongs to the technical field of CAR-T cells. The preparation method comprises the following steps: coupling bevacizumab and heparinase, immobilizing the coupled bevacizumab and heparinase on anti-CD3 / CD28 magnetic beads to prepare modified magnetic beads, resuspending CAR-T cells by using an MACS T cell culture medium containing potassium chloride, decitabine liposome and 2-deoxy-D-glucose, adding the modified magnetic beads, uniformly mixing, and performing magnetic field stimulation culture to obtain the high-activity CAR-T cells. The high-activity CAR-T cells prepared by adopting the large-scale amplification culture method of the CAR-T cells not only have better wettability, can enter a tumor microenvironment, but also can improve recruitment of the CAR-T cells in the tumor microenvironment, and have better anti-tumor activity, meanwhile, the amplification rate is obviously improved by adopting the method, and the method is suitable for large-scale in-vitro amplification culture.

Provided includes methods, compositions and kits for improving outcome of a treatment for colorectal cancer, and methods, compositions and kits for determining responsiveness of a subject to a treatment for colorectal cancer. Determining responsiveness can comprise determining change(s) in mean level of somatic mutations of at least three genes in the subject. The treatment for colorectal cancer can comprise administering PLK1 inhibitor (e.g., onvansertib) and bevacizumab to the subject.

The invention discloses injectable bioactive matrix hydrogel with an anti-angiogenesis and anti-neurogenesis microenvironment and application of the injectable bioactive matrix hydrogel. The injectable bioactive matrix hydrogel is prepared from bevacizumab, a concentrated growth factor and methacrylic acid chondroitin sulfate. The hydrogel prepared by the invention not only shows excellent injectability and biocompatibility, but also can inhibit pathological vascularization and neurogenesis, polarize macrophages to promote regeneration of M2 phenotype so as to relieve inflammation, and directly enhance deposition of cartilage specific ECM components (such as type II collagen and aggregation proteoglycan). By utilizing the coordinated multi-mechanism strategy, the comprehensive structure and function repair of the degenerated intervertebral disc is realized.

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin are provided. Methods of administering the combinations to treat cancer, e.g., ovarian cancer, with higher clinical efficacy and / or reduced toxicity are also provided.